Therapeutic Targeting of Human Prostate Cancer

描述（由申请人提供）：本次会议的广泛目标是将基础和临床科学家聚集在一起，讨论根除或预防前列腺癌的新治疗靶向策略。 其目标是加快发现前列腺癌预防、检测、诊断和治疗新知识的步伐，并将这些发现转化为实际应用。 前列腺癌是美国男性死亡的第二大原因。 前列腺癌具有其他上皮恶性肿瘤所不具有的独特特征。 目前，在理解疾病的分子进展事件方面取得了新的进展，并且存在临床相关的见解。 然而，治疗前列腺癌的新疗法的例子很少。 本次会议的目标是提供一个论坛，交流有关前列腺癌发展的分子基础的新信息和想法，并刺激转化研究，以解决该疾病的临床相关问题。 本次会议的结构是这样的，在每一次会议上，介绍了临床相关的特点和分子细胞生物学或遗传方面的疾病。 特别是，会议将强调细胞外基质及其受体，基质-上皮相互作用，遗传风险因素，早期靶向化学预防和前列腺成像的改变。 这是一次重要的首次会议，原因有二。 它为临床医生和科学家的互动提供了一个论坛，以研究临床相关问题背景下前列腺癌生物学的特定发现。 会议还将作为一个接口的基础上，前列腺的基本生物学的新的治疗策略的发展。 预计通过高度互动的会议交流信息和想法将有助于产生对前列腺癌预防和治疗产生影响的新概念和想法。

DESCRIPTION (provided by applicant): The broad objective of this conference is to bring together basic and clinical scientists to discuss new therapeutic targeting strategies for eradicating or preventing prostate cancer. The goal is to accelerate both the pace of discovery of new knowledge in the prevention, detection, diagnosis and treatment of prostate cancer and the translation of these discoveries into practical applications. Prostate cancer is the second leading cause of death of men in the United States. Prostate cancer has unique features not shared by other epithelial malignancies. Currently new advances have been made in understanding molecular progression event in the disease and clinically relevant insights exist. However, there are few examples of new therapies to treat prostate cancer. The goal of this meeting is to provide a forum for the exchange of new information and ideas concerning the molecular basis for prostate cancer development and stimulate translational research to solve clinically relevant problems in the disease. This meeting is structured such that within each session presentations are given on clinically relevant features and the molecular cellular biology or genetic aspect of the disease. In particular, sessions will emphasize alterations in the extracellular matrix and their receptors, stromal-epithelial interactions, genetic risk factors, early targeting for chemoprevention and imaging of the prostate gland. This is an inaugural meeting that is important for two reasons. It provides a forum for the interaction of clinicians and scientists to examine particular discoveries in prostate cancer biology within the context of clinically relevant issues. The meeting also will serve as an interface for the development of novel therapeutic strategies based upon the basic biology of the prostate gland. It is anticipated that the exchange of information and ideas through a highly interactive meeting will help generate new concepts and ideas that will have an impact on prostate cancer prevention and cure.